rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

AC Immune SA

ACIU · Nasdaq

Health CareBiotechnologyNot moving yet

ACIU stood above a rising 150-day average in 19 of the last 52 weekly readings, and has been out of that trend for the last 27 weeks. It is 8.2% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 27
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$63K
Insider sales, 12 months
$119K
Officials’ trades on record
0
Institutions holding
41 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 19 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$58K$0$58KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months2
Buyers · sellers1 · 1
WhoDidSharesTraded
Andrea PfeiferChief Executive Officersold10,000at $2.7915 May 2026filed 18 May 2026
Andrea PfeiferChief Executive Officerbought10,000at $3.1415 Apr 2026filed 16 Apr 2026
Andrea PfeiferChief Executive Officersold10,000at $3.1415 Apr 2026filed 16 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders41+0 on the quarter
New · exited6 · 6
Reported value$58.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BVF INCunchanged · filed 14 Aug 202619,822,436$47.2M00.0%
WELLS FARGO & COMPANYreduced · filed 14 Aug 20261,004,041$2.4M-2430.0%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026840,127$2.0M+215,760+34.6%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 2026773,594$1.8M-19,063−2.4%
BlackRock, Inc.reduced · filed 7 Aug 2026519,274$1.2M-5,004−1.0%
DIMENSIONAL FUND ADVISORS LPreduced · filed 11 Aug 2026340,082$812K-50,083−12.8%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPreduced · filed 13 Aug 2026232,953$554K-172,705−42.6%
CITADEL ADVISORS LLCreduced · filed 14 Aug 2026207,606$494K-59,627−22.3%
MORGAN STANLEYadded · filed 13 Aug 2026131,815$314K+42,562+47.7%
TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 2026102,825$245K+63,734+163.0%
31 Mar 2023 – 30 Jun 2026
243341Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Carl Howard June Company insiderDirector · last 11 Jun 20260 · 0
Martin Zuegel Company insiderInterim CEO · last 11 Jun 20260 · 0
Monika Buetler Company insiderDirector · last 11 Jun 20260 · 0
Renee Aguiar-Lucander Company insiderDirector · last 11 Jun 20260 · 0
Roy Ervin Twyman Company insiderDirector · last 11 Jun 20260 · 0
Andrea Pfeifer Company insiderChief Executive Officer · last 15 May 20261 · 2

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 31 Dec 20251.3%

Analyst forecasts

No analyst forecasts yet.